Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Sector Update: Energy Stocks Mostly Higher Early Monday

Sector Update: Energy Stocks Mostly Higher Early Monday

MT newswireMT newswire2026/10/12 13:32
09:32 AM EDT, 10/12/2026 (MT Newswires) -- Energy stocks were mostly higher in early trading Monday, with the State Street Energy Select Sector SPDR ETF (XLE) gaining 1.2%. The United States Oil Fund (USO) was up 2.1%, while the United States Natural Gas Fund (UNG) was 2.2% lower. Front-month US West Texas Intermediate crude oil was up 2% at $93.65 per barrel at the New York Mercantile Exchange. Global benchmark North Sea Brent crude oil rose 2% to $106.81 per barrel, and natural gas futures were 2.3% lower at $3.15 per 1 million British Thermal Units. DHT (DHT) shares were up nearly 4% after the company said it expects time charter equivalent earnings of $141,300 per day for its fleet in Q3. Marathon Petroleum (MPC) shares were up nearly 2% after Jefferies raised its price target for the company to $433 from $413. Phillips 66 (PSX) stock was 2% higher after Jefferies & Co raised its price target to $276 from $242.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56